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The  Molecular  Parasitology  conference  was ﬁrst held  at the  Marine  Biological  laboratory,  Woods  Hole,
USA 25  years  ago.  Since  that  ﬁrst  meeting,  the  conference  has evolved  and  expanded  but  has  remained  the
showcase  for  the  latest  research  developments  in molecular  parasitology.  In this  perspective,  I reﬂect  on
the scientiﬁc  discoveries  focussed  on  African  trypanosomes  (Trypanosoma  brucei  spp.)  that  have  occurred
since  the inaugural  MPM  meeting  and  discuss  the  current  and  future  status  of research  on these  parasites.
© 2015  The  Author.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).. Introduction
The Annual Molecular Parasitology Meeting started in Woods
ole on September 9th 1990 and, with the exception of the
ragically disrupted conference in September 2001 (when a mini-
eeting was held involving those able to attend), has hosted 300
r more delegates for 25 years. Woods Hole was the natural home
or the conference, it being the base of the long running Biology of
arasitism Summer School, and has provided many young molecu-
ar parasitologists with their ﬁrst exposure to a vibrant, sometimes
ntimidating, international research conference [1]. Although the
mphasis of the conference has changed over the years, such that
he early presence of (even then only a few) helminth molecu-
ar biologists diminished and apicomplexan biology has come to
ominate, a core focus on trypanosomes and particularly African
rypanosomes has remained. In this perspective, I reﬂect on thePlease cite this article in press as: Matthews KR. 25 years of African t
and new drug discovery. Mol  Biochem Parasitol (2015), http://dx.doi.o
reath-taking developments in our knowledge of the biology and
olecular biology of Trypanosoma brucei that have occurred over
he last 25 years and highlight the discoveries, technologies and
 Molecular Parasitology Meeting 25th anniversary Perspective review.
 Whilst this article was in preparation we heard of the passing of Elisabetta Ullu.
his  article, which overviews developments in trypanosome biology over 25 years,
learly underlines her enormous contributions, together with Christian Tschudi,
o  this ﬁeld. In both the area of RNA regulation and, more recently, developmen-
al  control her contributions were pivotal and transformational in our capabilities
nd understanding of trypanosome biology. As for so many others in parasitology,
lisabetta Ullu was  my mentor, supporter and friend.
∗ Tel.: +44 1316513639; fax: +44 131 651 3670.
E-mail address: keith.matthews@ed.ac.uk
ttp://dx.doi.org/10.1016/j.molbiopara.2015.01.006
166-6851/© 2015 The Author. Published by Elsevier B.V. This is an open access article uncontroversies that have made this conference such an exciting
event in our scientiﬁc calendar (Fig. 1A). I also consider, almost
certainly naively, how research into trypanosomes may  develop in
future. I emphasise also that this perspective is personal and not
comprehensive; I have certainly omitted many key discoveries and
debates either through poor recollection or through simply miss-
ing key sessions whilst in the Captain Kidd. Notably, I have focussed
on the developments in the molecular and cellular biology of try-
panosome parasites to the detriment of many of the biochemical
processes that have proved so fascinating over the last 25 years.
2. The genome
Although not formally published as a draft genome until 2005
[2], sequencing efforts underpinned many of the discoveries in
trypanosome biology far earlier. In the late 1980s the state of
the art represented chromosome walking along VSG gene tran-
scription units through the isolation of overlapping bacteriophage
lambda clones, allowing a description of the architecture and
gene composition of the telomeric expression sites [3–5]. Beyond
this, gene sequence analysis involved cloning from plasmid and
phage libraries after hybridisation with labelled cDNA or oligonu-
cleotide probes and, from the late 1980s, exploitation of the
recently-discovered PCR technology using (at the time expensive)
oligonucleotide primers. Systematic genome sequencing efforts
began with Chromosome Ia (funded initially by the WHO) andrypanosome research: From description to molecular dissection
rg/10.1016/j.molbiopara.2015.01.006
thereafter Chromosomes IX, X, XI and Chromosomes II-VIII, funded
by the Wellcome Trust and NIAID respectively, with leadership
from (among others) Sara Melville, Andy Tait and Keith Gull (in
the UK) and Elisabetta Ullu, Ken Stuart, George Cross and John
der the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. (A) Progress in trypanosome biology over the last 25 years. Developments in the understanding of trypanosome biology have been driven by the development of new
technologies (“Technology”), the availability of new datasets (“Molecular Cartography”) and through the utility of cytological and molecular markers or expression proﬁles
(“Phenotypic read out”) that have assisted the interpretation of genetic perturbations. These developments have progressed the ﬁeld from an era of description to one where
gene  function can be discovered and understood. B. Timescales of new drug discovery for African trypanosomiasis and molecular parasitological research. The major drugs
for  Human African Tryapnosomiasis are old, and there is an important need for new drugs. The development of molecular parasitology as a ﬁeld promises to accelerate new
drug  discovery through the identiﬁcation of important processes and targets in the parasite. However, the discovery and development of new drugs is slow and expensive
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much  that the impressive discoveries that have emerged from molecular parasitolog
n  increasing focus and resource investment into the search for new drug targets a
onelson (in the US). These efforts focussed on T. brucei TREU
27/4, a strain competent for progression through the entire life
ycle [6], though most lab research at the time and subsequently
as focussed on T. brucei Lister 427, which compromises some
iological characteristics (pleomorphism, efﬁcient tsetse passage)
or rapid growth in vivo and in vitro and a low frequency of anti-
en switching, this facilitating some studies on antigenic variation.
ince the publication of the genome for T. brucei (coincidently with
rypanosoma cruzi and Leishmania major),  assemblies of several
urther trypanosome genomes have been generated, including dif-
erent strains and species (T. congolense,  T. vivax, T. evansi,  T. grayi;
ttp://tritrypdb.org) whereas the difﬁcult to clone and assem-
le telomeric sequences have been derived through TAR cloning,
llowing expression site architectures to be compared across the
enome and between species [7,8]. All of these efforts, of course,Please cite this article in press as: Matthews KR. 25 years of African t
and new drug discovery. Mol  Biochem Parasitol (2015), http://dx.doi.
ave made an enormous contribution to our ability to interrogate
ene function, gene expression and genome regulation and almost
very publication today in trypanosome molecular parasitology
akes use in some way of the information generated, and made only now beginning to yield new potential new therapies. This has been driven by
plement to new biological understanding per se.
accessible through the efforts of the genome sequencers, curators
and bioinformaticians.
3. Antigenic variation
Trypanosome populations escape immune clearance by anti-
body responses through their capacity for antigenic variation. The
protein responsible, the variant surface glycoprotein, was well
characterised in 1990, and the structure solved to 2.9-angstrom res-
olution [9]. The N- and C-terminal domains provide for antigenic
diversity and membrane association, respectively, with antibod-
ies being inaccessible to the more conserved membrane-proximal
domain on live parasites [10]. The protein is anchored to the
lipid membrane via the glycosylphosphatidylinositol (GPI) lipid
anchor and the pathway of its assembly was  established 25 yearsrypanosome research: From description to molecular dissection
org/10.1016/j.molbiopara.2015.01.006
ago [11–13]. However, since then characterisation of the enzymes
involved in the synthesis and addition of this essential component
of the surface coat of the parasite has provided a detailed descrip-
tion of its assembly pathway, these steps also providing potentially
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xcellent targets for drug development efforts [14–16]. The ﬂuid-
ty of the VSG on the parasite surface enabled by GPI anchoring
nd its rapid recycling by the parasite [17] also revealed a new
acet of the VSG’s contribution to immune evasion, namely hydro-
ynamic ﬂow [18]. Here, bound antibodies are swept towards the
agellar pocket of the parasite for endocytosis through the swim-
ing action of the parasite in blood. Although this only delays the
nevitable destruction of the parasite as antibody titres increase,
he increased survival time of the parasite might provide a useful
omponent of their infection dynamics immediately prior to clear-
nce of a given variant type by the immune system. Hydrodynamic
ow is particularly effective on transmission stage stumpy forms
f the parasite, and its action might therefore prolong the lifespan
f these irreversibly arrested parasites, increasing their probability
f tsetse uptake.
In the late 1980s, a combination of run-on transcription analysis
nd analysis of the sensitivity of transcription units to UV-induced
ucleotide dimerization demonstrated that VSG expression sites
ere polycistronic [3,5,19,20], with a distant upstream promoter
riving transcription through a number of expression site associ-
ted genes (ESAGs) before reaching the telomere-proximal VSG
ene itself. The polymerase responsible for transcription was
nown to be unusual, with RNA polymerase II (polII) lacking
he conventional C terminal extension [21], and inhibition stud-
es using the RNA polII inhibitor alpha amanitin having indicated
hat VSG expression site transcription was mediated by RNA poly-
erase I (polI) [22–24]. Formal biochemical support for this using
n vitro transcription assays and polymerase subunit depletion was
rovided in 2003 from the Gunzl lab [25], with the unusual nature
f the polI complex being subsequently revealed by afﬁnity puriﬁ-
ation [26].
The mechanism of antigen switching was also well charac-
erised before 1990, with a classical cassette-based model for VSG
witching, whereby intact antigen encoding genes were activated
ither by changes in the activity of an expression site (from around
5 to 20) or from translocation into an active expression site by
ene conversion or reciprocal telomeric exchange [27,28]. With a
arge repertoire of VSG genes available in the trypanosome genome
>1000 based on hybridisation studies; [29]) this provided a signif-
cant pool of available antigen types to ensure long-term immune
vasion. Although this model provided a textbook mechanistic
asis for the gene rearrangements associated with antigen switch-
ng in trypanosomes, analysis of the genome revealed that it was
n oversimpliﬁcation. Rather than a pool of intact VSG genes, the
enome was found to contain a majority of incomplete VSG genes
hat required to be assembled into functional mosaics [30,31]. This
as a surprise, with immediate implications for the potential size of
he available VSG repertoire (essentially inﬁnite) and also the prob-
bility of VSG gene activation and the ordering of the appearance
f new antigen types [32].
The existence of several expression sites raised the question
f how exclusive activation of only one expression site at a time
as achieved, and also why more than one expression site was
ecessary. The ﬁrst of these questions was resolved by the discov-
ry of an extranucleolar RNA polymerase I transcription factory,
ermed the expression site body (ESB) [33]. This provided a posi-
ional and structural entity where monoallelic exclusion could be
chieved through the restricted association of only one telom-
ric expression site to the ESB at any one time, with control
eing assisted by epigenetic mechanisms. Recently regulators of
he telomere silencing machinery have been uncovered, bringing
olecular understanding of the long-recognised stringent controlPlease cite this article in press as: Matthews KR. 25 years of African t
and new drug discovery. Mol  Biochem Parasitol (2015), http://dx.doi.o
f ES repression [34–37]. Although both VSG and procyclins, the
urface proteins expressed on the procyclic stage of the parasite,
re both polI transcribed, the ESB was bloodstream form speciﬁc,
ith telomeric association with the nuclear periphery being lost PRESS
l Parasitology xxx (2015) xxx–xxx 3
during differentiation from the bloodstream to the procyclic forms.
In procyclic forms procyclin transcription is nucleolar [38].
A potential answer to the second question, a reason for the exist-
ence of more than one expression site, was suggested after the
discovery that the promoter-proximal expression site associated
genes, ESAG6 and 7, encoded a heterodimeric receptor, respon-
sible for the uptake of iron from the host bloodstream in the
form of transferrin [39]. The existence of microheterogeneity in
the ESAG6 and 7 sequences from different expression sites led to
the hypothesis that different expression sites might be optimised
for transferrin uptake in different hosts [40], which exhibit sub-
tly different transferrins. This attractive model proposed that the
activity of different ES would provide a growth advantage in dif-
ferent host sera, but experimental support remains equivocal [41].
A second expression site associated gene, ESAG4, was  known to
encode an adenylate cyclase activity [5,42] although its function
was unclear until recently. Studies focussed on the early infection of
parasites expressing a dominant negative form of ESAG4 (necessary
because the large number of ESAG4 genes in the genome precluded
either gene knockout or gene silencing approaches) revealed that
parasites were less able to establish infection in a mouse model
[43]. This was proposed to be due to the effect of the ESAG4 activ-
ity on macrophages when trypanosomes were phagocytosed, the
consequence of which was to inhibit macrophage activation and
so promote the survival of parasites still circulating in the blood-
stream. Other expression site associated genes remain of cryptic
function although three (ESAGs 1, 2 and 8) have been reported to
be involved in the developmental capacity of parasites undergo-
ing VSG switching [44], with one of these (ESAG8), proposed to be
nucleolar, also being potentially involved in translational regula-
tion through the action of Puf proteins [45,46].
4. Human serum resistance and trypanolytic factors
Although the function of many ESAGs remains unclear, one
ESAG, found only in T. brucei rhodesiense, has a conﬁrmed role in
the resistance of these parasites to human serum trypanolytic fac-
tors. Raymond Hamers identiﬁed mRNAs associated with parasites
that were resistant to human serum lysis [47,48] and after involve-
ment with Patrick De Baetselier, Etienne Pays demonstrated the
gene responsible for conferring resistance was an expression site
associated gene apparently derived from a VSG sequence, termed
serum resistance associated (SRA) [49]. SRA was found in a trun-
cated expression site and its expression was  directly linked to
serum resistance, both in parasites that ﬂuctuated in their serum
resistance phenotype (due to different expression site usage, where
only one expression site contained SRA) and in transgenic T. brucei
engineered to express SRA. Indeed, SRA was found to be diagnos-
tic for T. b rhodesiense providing a key ﬁeld tool to identify human
infective parasites circulating in a zoonotic infection cycle [50,51].
The mechanism of SRA action and the trypanolytic components
of human serum have been controversial over the last 25 years,
but a consensus has emerged. Human serum contains trypanolytic
activities within high density lipoprotein (TLF1) and IgM complexes
(TLF2). TLF1, which contains haptoglobin-related protein (HPR) in
complex with haemoglobin, is taken up by trypanosomes through
their haptoglobin/haemoglobin receptor (TbHpHbR) [52]. TLF2, in
contrast, does not enter the trypanosome via the TbHpHbR but
instead seems to be internalised after relatively non speciﬁc inter-
action, possibly with the VSG at the parasite surface. This pathway
is more relevant at physiological concentrations of HPR, whererypanosome research: From description to molecular dissection
rg/10.1016/j.molbiopara.2015.01.006
haptoglobin concentrations render the TLF1 pathway likely inop-
erative through receptor competition [53,54]. Both TLF1 and TLF2
mediate trypanosome killing through the action of ApoL1 [55,56],
which inserts in the endosomal membrane and, upon entering the
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ysosome permeabilizes the membrane causing swelling through
hloride ion inﬂux and then osmotic lysis. Resistance in T. b. rhode-
iense is mediated through SRA binding to ApoL1 during trafﬁcking
o the lysosome, which inactivates its lysosomal pore forming capa-
ilities [57,58].
The SRA gene is absent in T. b. gambiense,  where human serum
esistance is mediated by an alternative protein also apparently
erived from a VSG sequence [59,60]. This molecule, TgsGP, acts
o rigidify the lysosomal membrane, rendering it less susceptible
o permeabilization by ApoL1, thereby preventing parasite lysis
60]. Uptake of TLF1 is also limited in T. b gambiense parasites
y inactivation of the TbHpHbR, which prevents parasite killing
nder conditions of hypohaptoglobinaemia, common in malaria
ndemic regions through selection for the sickle cell trait. Recep-
or inactivation was necessary because affected individuals release
aemoglobin reducing the abundance of haemoglobin-haptoglobin
omplexes [61], favouring the TLF1 pathway.
As well as parasite adaptive mechanisms, trypanosome hosts
ave also evolved effective countermeasures to protect them-
elves from parasite infection. The evolution of APOL1 in old world
onkeys conferred resistance to Trypanosoma brucei spp., whereas
n baboons the ApoL1 C-terminal sequence enables trypanolytic
ctivity even in the presence of SRA [62]. This represents an inter-
sting potential response to the evolution of trypanosomes able
o escape ApoL1 mediated lysis, a phenomenon also detected in
uman populations where two mutations in ApoL1 are enriched
n populations of recent African origin, albeit with a concomitantly
ncreased risk of kidney disease [63,64].
. Cell structure, cell cycle and life cycle
The ﬁrst quantitative temporal descriptions of the trypanosome
ell cycle were published in 1989 [65], with the kinetoplast and
uclear replication and division cycles being described in 1990 [66].
hese have provided the template for many analyses of pheno-
ypes generated upon gene depletion by RNAi and gene knock out.
or the complex network of kinetoplast DNA, minicircle replica-
ion has been found to involve detachment from the compacted
DNA network, replication at antipodal replication sites, followed
y reinsertion into the network [67,68]. The kDNA is itself seg-
egated through attachment to the basal body via a ﬁlamentous
etwork, the tripartite attachment complex [69], that spans from
he kinetoplast DNA, through the mitochondrial membrane, attach-
ng ultimately to the basal body of the trypanosome ﬂagellum.
he molecular components of this machinery have started to be
dentiﬁed [70–72], with one component, AEP1, apparently being
enerated by the alternative RNA editing of COXIII transcripts [73].
ailure to successfully replicate or segregate the kDNA results in
he generation of dyskinetoplastid (DK) parasites, lacking a mito-
hondrial genome. Although these are inviable in the insect vector,
K parasites can survive in the bloodstream in the presence of a
utation in the F1FO ATPase gamma  subunit that allows them to
enerate a mitochondrial membrane potential in the absence of
DNA-encoded factors [74,75].
For nuclear DNA, early pulsed ﬁeld gel electrophoresis stud-
es of the chromosome events associated with antigenic variation
ad revealed the existence of large numbers of minichromosomes,
s well as the 11 diploid chromosomes [76,77]. The minichromo-
omes apparently increase the pool of telomeric VSG genes for
ntigenic variation, but necessitate a distinct spindle apparatus to
hat of higher eukaryotes to allow chromosome segregation in thePlease cite this article in press as: Matthews KR. 25 years of African t
and new drug discovery. Mol  Biochem Parasitol (2015), http://dx.doi.
bsence of a kinetochore and microtubule structure for each and
very chromosome. This is achieved through microtubules that
un pole–pole, allowing 50–150 kB minichromosomes to be segre-
ated with ﬁdelity [78]. For the megabase chromosomes, the site of PRESS
l Parasitology xxx (2015) xxx–xxx
kinetochore binding at centromeres was unclear until a recent
iterative immunoprecipitation process allowed the isolation of a
coherent kinetochore protein complex unlike that identiﬁed in any
eukaryote to date [79]. The replication machinery for nuclear DNA
is also unusual, particularly in the formation of the early replication
complex. Nonetheless, the components are beginning to be eluci-
dated and this reveals features in common with other eukaryotes,
including the presence of multiple, albeit widely spaced, origins
perhaps to avoid interference with the transcription machinery
operating on the long polycistronic transcription units that char-
acterise gene organisation in kinetoplastid parasites [80,81].
As well as the as DNA containing organelles, there has been
considerable focus over the last 25 years on the structure of the
other single copy organelles within the trypanosome cell. A partic-
ular focus has been on the ﬂagellum, where the genetic tractability
of trypanosomes has provided an excellent model for eukaryotic
ﬂagellar biology, an area of signiﬁcant and widespread interest
through the role of ﬂagellar and cilia defects in several human
diseases [82–84]. The ﬂagellum comprises the conventional 9 + 2
axoneme plus an associated paraﬂagellar rod structure that assists
parasite swimming [85]. In the procyclic forms of the parasite, posi-
tional information for ﬂagellar duplication is provided by a ﬂagellar
connector structure that ensures that the new ﬂagellum tracks
along the path of the old ﬂagellum [86] with a subpellicular ﬂagel-
lum attachment zone zippering the ﬂagellum along the cell body.
Whilst fundamental, the absence of an easily recognisable ﬂagellum
connector in bloodstream form parasites [87] remains a conun-
drum. Protein trafﬁcking along the ﬂagellum during its growth and
once established is achieved via intraﬂagellar trafﬁcking similar
to the process seen in other eukaryotes [82]. This is accompanied
during outgrowth of a daughter ﬂagellum by detailed positional
restructuring as the ﬂagellum emerges from the parasite’s ﬂagellar
pocket, a precisely organised invagination of the cell surface that
controls membrane recycling and exchange with the environment
[88]. This establishes the correct cellular architecture necessary for
the production of a viable daughter cell [89].
The same problem accompanies the replication and segregation
of other single copy organelles. The Golgi, for example, is segre-
gated in association with a bilobe structure [90,91] located close
to the mouth of the ﬂagellar pocket and aligned with the ﬂagellar
attachment zone. This complex is replicated with ﬁdelity in pro-
cyclic forms, but less so in bloodstream forms. The secretory path
is also similar to that of other eukaryotes but tuned for efﬁcient
VSG trafﬁcking in the bloodstream forms [92]. Indeed, endocyto-
sis is far more active in bloodstream forms than procyclic forms,
with Rab11 apparently being a key player in the process, acting in
concert with other conserved and evolutionarily divergent compo-
nents of the endocytic apparatus to enable VSG recycling and the
removal of VSG associated immunoglobulins via the lysosome [93].
The mitochondrion also requires replication and segregation of its
genome, as well as duplication and segregation of the organelle
itself. Both processes depend on import of nuclearly encoded mito-
chondrial proteins. The import machinery is not well conserved
with respect to other eukaryotic organisms and instead the basic
outer membrane import protein was  suggested to be of bacterial
origin [94]. A further organelle type linking eukaryotic and prokary-
tic cellular evolution was the discovery of acidocalcisomes in T.
cruzi by Roberto DoCampo [95]. These provide an acidic calcium
store enriched in Pi, PPi and polyphosphate and have been found
in other kinetoplastids, but also apicomplexans, Chlamydomonas,
bacteria and also metazoa – suggesting their origins prior to the
divergence of eukaryotic and prokaryotic cells [96]. These appearrypanosome research: From description to molecular dissection
org/10.1016/j.molbiopara.2015.01.006
to have shared functions to control osmotic balance as well as cation
and phosphate stores, with the discovery of IP3R in the acidocal-
cisomes of trypanosomes also indicating a role in cell signalling
[97,98].
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. Life cycle
Life cycle events differ importantly between different African
rypanosome species, but most understanding and progress has
een made with T. brucei.  In the 1980s almost all laboratory work
ocussed on laboratory-adapted bloodstream form lines, termed
onomorphs, and long-term cultured procyclic forms. However, in
990 Ziegelbauer and colleagues [99] described the synchronous
ifferentiation of bloodstream to procyclic forms using pleo-
orphic parasites (i.e. those capable of generating transmissible
tumpy forms, a trait reduced in laboratory-adapted monomor-
hic lines) stimulated by the differentiation triggers citrate and
is-aconitate. This enabled the tractable dissection, in vitro, of
evelopmental events as parasites differentiated from arrested
loodstream stumpy forms, which accumulate at peak of par-
sitaemic waves in rodent infections, to procyclic forms. Early
tudies established that stumpy forms were uniformly arrested
n their cell cycle in G1 [100,101] and underwent a simultaneous
ell cycle re-entry and differentiation within a matter of hours
n vitro, with differentiation competence proposed to be linked
o cell cycle arrest in G1/G0 [101]. Soon after differentiation the
arasites express different isoforms of the procyclic form surface
oat, initially EP and GPEET procyclin (early procyclic forms) but
hen only EP procyclin (late procyclic forms) [102–104]. In the
y’s salivary glands, the insect forms undergo further develop-
ent to epimastigote forms after an asymmetric division, where
hey express a new surface protein BARP, this eventually being
eplaced by VSG upon differentiation to metacyclic forms [105]. The
hysiological stimuli for the various developmental events during
he life cycle remain unclear in most cases, though the produc-
ion of stumpy forms seems to be stimulated by a parasite-derived
ignal termed stumpy induction factor [106]. Whatever the spe-
iﬁc molecular trigger, numerous components of the signalling
esponse pathway required for slender-to-stumpy differentiation
ave recently been characterised [107]. Once generated, stumpy
orms are able to perceive entry into the tsetse ﬂy through their
xpression of the surface PAD family of proteins that convey the
itrate/cis-aconitate signal [108], to which they are hypersensitive
t low temperature [109]. Signalling upon entry into the tsetse ﬂy
s mediated by a phosphatase-signalling cascade that is trafﬁcked
o the glycosomes [110–112].
After differentiation from early to late procyclic forms, an event
romoted by hypoxia and/or glycerol exposure in vitro [102],
rocyclic forms multiply until passage through to the salivary
lands, where epimastigotes form after an asymmetric division
113,114]. The journey to the salivary glands represents a strong
ottleneck in the life cycle of the parasite [115], after which epi-
astigotes multiply whilst attached to the salivary gland wall.
ome of these cells then undergo meiosis and sexual exchange,
hese events having been visualised by the expression of con-
erved meiosis speciﬁc proteins [116] and the appearance of fused
ells after dual infection of tsetse ﬂies with parasites express-
ng either red or green marker proteins, generating yellow cells
117].
Finally metacyclic forms are produced, which are arrested in
ivision and re-express the VSG in preparation for infection of new
ammalian hosts. Recapitulating in vitro the generation of meta-
yclic forms in the salivary glands from epimastigote forms has
ecently been achieved for T. brucei,  this being driven, albeit inef-
ciently, by the overexpression of a small RNA binding protein,
BP6 [118]. This highlights that single protein expression changes
an drive surprisingly complex developmental events, an observa-Please cite this article in press as: Matthews KR. 25 years of African t
and new drug discovery. Mol  Biochem Parasitol (2015), http://dx.doi.o
ion reinforced by the morphological events induced by perturbed
xpression of the ALBA 3 and 4 proteins [119] and a calpain-like
rotein [120] and gene regulatory changes linked to perturbing the
NA helicase DHH1[121] PRESS
l Parasitology xxx (2015) xxx–xxx 5
7. Post-transcriptional gene expression regulation
The organisation of the trypanosome genome into polycistronic
transcription units was established in the late 1980s, reﬂecting that
it was not only the VSG gene transcription unit that contained mul-
tiple genes but that this was a general genome-wide phenomenon
[122,123]. Despite this multi-gene organisation, there remains lit-
tle evidence for co-regulated operons such that the emphasis of
gene regulation in trypanosomes is post-transcriptional. Transcrip-
tion is initiated at the boundary of, and in some cases within,
monodirectional gene clusters from ill-deﬁned polymerase II pro-
moter sequences marked by an enrichment of the histone variants
H4K10ac, H2AZ, H2BV, H3 V and H4 V and the bromodomain pro-
tein BDF3 [124]. The transcription complex and the structure of
individual transcription factors is unusual [125–127], with the
primary transcripts from polycistronic transcription units being
co-transcriptionally processed by trans splicing at the 5′ end of
each mRNA and polyadenylated at the 3′ end, in a mechanistically
coupled process [128]. The paradigm that there is an absence of
cis-splicing still holds true for almost all genes in the trypanosome
genome, although two  genes have been discovered that exhibit
cis-splicing [129], and the importance of alternative splicing to cre-
ate distinct protein products, or proteins with altered localisation
signals is becoming apparent [130,131]. Transcription termination
at the boundaries of polycistronic transcription units appears to
be associated with an accumulation of the Base J [132], a novel
nucleotide produced in trypanosomes by the action of two  biosyn-
thetic enzymes [133].
To achieve differential mRNA abundance for transcripts derived
from the same transcription unit, differential mRNA stability seems
to be the dominant mechanism of control. The most deﬁnitive early
studies focused on the procyclin mRNAs, where the focus of regu-
lation operates through the 3′ UTR (though transcriptional control
also contributes to this RNA polI transcribed gene family) [134].
Both positive and negative elements were mapped using reporter
assays, suggesting the existence of regulatory loops controlling
mRNA stability/instability and translational efﬁciency. For GPEET
procyclin, environmental factors were also able to regulate devel-
opmental expression, such that the 3′ UTR contained sequence
motifs responsive to the presence of environmental glycerol or
hypoxia [102]. The focus of gene regulation on the 3′ UTR of reg-
ulated genes has remained a common theme through the analysis
of many differentially expressed genes and gene families, but the
identiﬁcation of conserved linear or obvious secondary structural
motifs has remained challenging. This partly reﬂects the difﬁcul-
ties in accurately predicting folding proﬁles for mRNA sequences
by computational means alone, but also is a likely consequence of
the use of multiple combinations of different regulatory RNA bind-
ing proteins to achieve complex regulatory events for co-regulated
gene products.
Consistent with the post-transcriptional focus of gene reg-
ulation in trypanosomes, the parasite genome encodes a large
repertoire of potential RNA regulators, some with conﬁrmed func-
tions in the control of stage-regulated genes [135]. After 15 years
effort, regulators of procyclin mRNAs have emerged [136,137], and
more recently a regulatory factor controlling many membrane-
associated proteins has been identiﬁed [138], as has a stem-loop
structure present on purine responsive genes [139]. In addition
to these speciﬁc regulatory factors and sequences, more general
regulatory factors have been characterised in detail. Hence, the
core machinery linked to mRNA decay has been characterised and
conserved components of the translational apparatus have beenrypanosome research: From description to molecular dissection
rg/10.1016/j.molbiopara.2015.01.006
described [140,141]. As well as these machineries, the molecular
cartography of gene expression and protein expression changes
associated with different tractable parasite life cycle stages has
been achieved, starting with differential display and subtractive
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ybridisation approaches, and thereafter by genomic arrays and
icroarrays, SAGE and RNA-Seq [142] and, most recently, SILAC
roteomics and phosphoproteomics [143,144], ribosome proﬁling
145] and description of the small proteome [146]. These have led
o increasingly detailed descriptions of the molecular proﬁle of try-
anosome developmental forms such that published differences
re now less due to differences in methodology and resolution and
ore due to biological differences (media, isolation procedures,
trains, growth characteristics, etc.).
Whether speciﬁc genes are perturbed or not, these outputs all
rovide data resources that will hopefully allow interconnected
egulatory events to be understood, clarifying how transcriptional,
RNA processing, mRNA turnover, translational and post transla-
ional regulatory events are integrated to generate a physiological
esponse. This kind of integrated modelling at the biochemical level
as pioneered in the trypanosome system through the genetic and
iochemical analysis of glycolytic compartmentation in specialised
eroxisomes, the glycosomes [147–149]. This revealed that com-
artmentation of the glycolytic enzymes within the glycosomes
as a key parameter to prevent glycolysis running out of con-
rol through the turbo design of the process, given the lack of
eedback control mechanisms typical for other eukaryotes. This
terative interaction between mathematical prediction and exper-
mental observation provided one of the earliest examples of a
ystems approach to understand biological networks [150], and
as considerable potential to identify vulnerable biochemical con-
rol points to target pharmacologically. Many of these have been
dentiﬁed over the last 25 years, highlighting that trypanosomes
xhibit extreme biochemical diversity as well as molecular and
ellular diversity between life cycle stages and between differ-
nt trypanosome species [151,152]. Highlighting these distinctions,
loodstream forms of the parasite use acetate produced in the
itochondrion via an ‘acetate shuttle’ and threonine to generate
atty acids, a process which is lethal if inhibited [153]. Similarly
ipid biosynthesis in trypanosomes differs from mammalian hosts,
ffering targets for chemotherapy [154,155].
As well as nuclear gene expression, mitochondrial gene expres-
ion has remained an area of intense research activity. In 1990 the
henomenon of RNA editing was well established, with the role of
he guide RNAs as templates of the process, and minicircles as the
ource of gRNA genes being reported in that year [156,157]. The
echanistic details of the process have been ﬁlled in considerably
ince then, with components of the editing machinery (the edito-
ome) being identiﬁed, and uridine insertion and deletion activities
haracterised [158]. When combined with the RNA components,
he 20S editosome protein complex – which contains the reaction
entre that achieves mRNA cleavage, U insertion or deletion and
eligation – has been proposed to form a 35–40S complex [158].
hilst this description of the components and action of the differ-
nt subunits of the editosome has advanced signiﬁcantly, providing
otentially important drug targets [159], it emerged that editing
s but one component of a complex mitochondrial gene expres-
ion network, with pentatricopeptide repeat-containing proteins
ssuming a key role [160]. A clear hypothesis for the function of the
nergetically expensive editing process remains elusive, although
ntriguing possibilities for how and why it might have evolved have
een proposed [161,162].
. Genetic tools to understand gene function
The rapid experimental advances over the last 25 years detailedPlease cite this article in press as: Matthews KR. 25 years of African t
and new drug discovery. Mol  Biochem Parasitol (2015), http://dx.doi.
bove have been enabled by a series of technical breakthroughs
uch that trypanosomes now represent one of the most tractable
icrobial eukaryotes. In 1990, transient transfection of try-
anosomes was possible [163,164] and the ﬁrst MPM  meeting PRESS
l Parasitology xxx (2015) xxx–xxx
reported homologous recombination of constructs into the try-
panosome genome allowing the selection of the stable transgenic
parasite lines needed for biochemical and molecular analysis. This
was a key breakthrough since prior to that point the sophisticated
molecular analyses of trypanosomes were necessarily descriptive.
However, with gene knockout feasible through efﬁcient homol-
ogous recombination, the ability to create null mutants, or to
ectopically overexpress genes allowed experimental intervention
and phenotypic analysis to uncover novel biology. Key to these
early analyses was  the development in the Clayton and Cross
laboratories of inducible expression systems based on the incor-
poration of tetracycline operator sequences into the identiﬁed
procyclin gene promoter, and subsequently T7 RNA polymerase
promoter, such that expression could be regulated by tetracy-
cline in a cell line expressing the tetracycline repressor protein
[165–167]. Although this allowed the development of conditional
knockout out approaches to analyse gene function, the diploid
genome of the parasite in both bloodstream and procyclic forms,
and the relative inefﬁciency of stable transfection (particularly in
the bloodstream form) meant that the analysis of genes was labo-
rious and low throughput.
In 1998 a dramatic technical development was achieved
through the identiﬁcation by Elisabetta Ullu’s laboratory of an
active RNA interference pathway in T. brucei,  essentially contem-
poraneously with its discovery in other systems [168]. Initially
discovered through the cytoskeletal perturbation generated (‘FAT’
phenotype) after the expression of a double stranded RNA seg-
ment derived from the tubulin gene locus, the ability to effectively
silence gene expression in trypanosomes by the expression of dou-
ble stranded RNA derived from a target gene of interest (generated
either as two  complementary transcripts from opposing promoters
[169,170] or as a single ‘stem loop’ transcript [171,172]) has revo-
lutionised gene function analysis. In a single round of transfection
into a cell line already expressing the tetracycline repressor, genes
could be silenced or not by the inclusion or absence of tetracy-
cline in culture medium, or doxycycline in the water of infected
rodents. Importantly, the organelle and cell structural markers
characterised earlier provided the simple phenotypic assays to
monitor effects on cell shape and cell cycle progression, providing
rapid visual clues to the function of silenced genes. Since its dis-
covery, over 500 papers have described the use of RNAi to analyse
gene function in trypanosomes [173], reﬂecting the rapid applica-
tion of this important tool in trypanosome cell molecular biology,
this being assisted by many improvements and reﬁnements in the
sophistication of constructs used for transfection and the increasing
availability of selectable markers.
As well as using RNAi for reverse genetic analysis of gene
function, it is increasingly used as a tool for forward genetic selec-
tion. The ﬁrst genome wide RNAi library was created in Paul
Englund’s lab, which applied concanavalin A binding selection to
isolate parasites unable to produce EP procyclin [174].  This identi-
ﬁed hexokinase silencing as an unexpected regulator of procyclin
expression but was  laborious, requiring 5 × 109 parasites to be
transfected in 50 transfections to provide sufﬁcient genome cov-
erage.
For bloodstream forms, the lower transfection efﬁciency pre-
cluded forward genetic approaches until higher efﬁciencies were
achieved through the use of Amaxa nucleofector technology [175].
Integration efﬁciency was  also improved by the creation of targeted
double stranded breaks using a meganuclease that acts as a catalyst
for homologous recombination at a speciﬁc target site [176–178].
Through these approaches genome-wide phenotypic approachesrypanosome research: From description to molecular dissection
org/10.1016/j.molbiopara.2015.01.006
became feasible in the disease-relevant bloodstream form of the
parasite, selections ﬁrst being applied to drug resistance mecha-
nisms. After exposure of RNAi libraries to different therapeutically
important drugs, genes whose silencing allowed survival could be
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dentiﬁed by isolation of the RNAi inserts enriched in the selected
opulations by PCR ampliﬁcation. This resulted in the simulta-
eous conﬁrmation of the AAT transporters as a resistance target
or eﬂornithine in the Horn and Roditi labs [179,180], with this
eing followed up by high throughput analysis of selected inserts
y RIT-Seq analysis [181]. Application of this approach to identify
ssential genes [181], genes linked to drug resistance [182], and
ubsequently to genes associated with quorum sensing pathways
n the parasite [107], have provided detailed insight into important
henomena in the parasite unbiased by prior knowledge. This rep-
esents an enormously powerful beneﬁt of this approach, which is
ble to associate genes of no known function with selectable phen-
types, providing a genome-wide annotation of hypothetic protein
lasses of otherwise unpredictable function.
. Drug discovery
In the last 25 years there has been an explosion in research
irectly focused on therapies for African trypanosomiasis, with 21%
f manuscripts in 1990 mentioning ‘drug + brucei’ vs. ‘brucei’ alone
89/418 papers) whilst in 2013, this had increased to 41% (275/666
apers). This effort has not been accompanied by the emergence of
any new drugs to treat the disease, but very promising progress
s being made (Fig. 1B). In 1990, eﬂornithine was ﬁrst licensed
or use against T. b. gambiense,  and since then NECT (nifurtimox
ﬂornithine combination therapy; launched in 2009) has also been
pplied successfully. This reduces the time needed for treatment
rom 14 to 10 days and the number of intravenous doses required
s reduced by 75%, with an overall halving of the therapeutic cost
183]. Major effort has also been put in to the development of
nhibitors for new targets identiﬁed as essential to the parasite after
xperimental validation, genome prediction of pathway dependen-
ies or from cell based high throughput screening of drug libraries
gainst parasites in culture. Target based approaches have identi-
ed N-myristoyl transferase as potentially suitable for therapeutic
nhibition [184] but for other targets molecular or in vitro inhibition
ssays have not always proven reliable indicators of in vivo efﬁcacy
185]. In consequence there has been some shift in focus away from
olecular targets deﬁned a priori towards high throughput pheno-
ypic screening to rapidly identify cell permeable inhibitors that
re toxic to the parasite but not host cells. This has been enabled by
he development of robotic screening approaches and partnerships
etween academia and pharmaceutical companies allowing access
o expertise, equipment and compound libraries not otherwise
vailable or practicable in a university setting. Promising outcomes
rom this phenotypic screening approach have been development
f the orally effective drugs fexinidazole, which is currently in phase
II clinical trials and oxaborole SCYX-7158 in phase I clinical trials
186].
These efforts provide encouragement that effective new ther-
pies will be delivered for human African trypanosomiasis, but
ajor challenges to disease control remain. Firstly, drug develop-
ent is enormously expensive yet trypanosomiasis therapy offers
o prospect of a commercial return. This places the emphasis of
rug development on governments, charities and industrial phi-
anthropy, when other diseases demand greater attention or are
ore immediately pressing. This challenge has been met by the
stablishment of effect public–private partnerships, for example
NDi, bringing partners together to establish collaborations and
ccelerate drug development. Secondly, any developed therapies
ay be beyond the health budgets of afﬂicted regions, particu-Please cite this article in press as: Matthews KR. 25 years of African t
and new drug discovery. Mol  Biochem Parasitol (2015), http://dx.doi.o
arly those facing ongoing political and economic upheaval. Thirdly,
ue to a decrease in the number of cases of human African
rypanosomiasis in recent years the impact of trypanosomiasis
n humans is now largely indirect, through the effects of the PRESS
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parasite on livestock. However, the major livestock trypanoso-
matids, T. congolense and T. vivax, have not been the focus of most
drug screening efforts and their biology and biochemistry may  be
sufﬁciently different to restrict drug efﬁcacy, a point well illustrated
by the relative insensitivity of T. b. rhodesiense to eﬂornithine when
compared to T. b. gambiense [187]. Moreover, the mode of action
of drugs used against the livestock parasites is relatively unex-
plored with even ethidium bromide (a commonly used trypanocide
in livestock) only being recently characterised[188]. Finally, the
importance of trypanosomiasis as a zoonosis is often overlooked,
such that preventing human infection requires animal infections to
be speciﬁcally and actively targeted [50], a major challenge given
the broad host range of human infecting trypanosomes.
Despite these challenges, molecular parasitology has offered
direct opportunities for control, an example being the exploitation
of the mechanism of human resistance to animal trypanosomes
through the engineering of cattle expressing APOL1 [189]. Con-
versely, drug screening efforts have the potential to provide new
biological insight, through the identiﬁcation of tool compounds
that assist the dissection of biological processes particularly when
in combination with genome wide approaches to identify molecu-
lar pathways perturbed by particular inhibitors [190]. Hence, there
is every prospect that brute force drug screening efforts will reap
rewards not only in new therapies, but also through illuminating
areas of parasite biology that would otherwise not be predicted
through conventional hypothesis-driven research.
10. Future perspectives
The last 25 years of research into African trypanosomes has
uncovered many key aspects of the parasite’s biology. During this
time, the number of human cases of the disease have increased
and then decreased again, such that current reported cases are
less than 10,000 per year. Although this has raised hopes for the
elimination of the disease, it is cautionary to note that the level of
infections currently are still higher than in the 1960s and that the
main foci of human infections, the Democratic Republic of Congo,
Central African Republic and South Sudan are currently undergo-
ing violent political unrest, conditions that are ideal for resurgence
of trypanosomiasis in the coming years. Furthermore, the livestock
disease continues to have major impact throughout sub-Saharan
Africa, and resistance is an increasing problem for farmers, not least
due to the unregulated drug supply chain.
Trypanosomes have also maintained their position as fascinat-
ing biological models and, through their evolutionarily divergent
position, have continued to reveal novel phenomena that inform
all of eukaryotic biology. Recent examples include the unusual epi-
genetic mechanisms that trypanosomes exhibit [124], their novel
mechanisms of chromosome segregation [79] and ﬂagellar biology.
This novelty is important and maintains trypanosomes as an inter-
esting system for general molecular and cell biologists, particularly
given the range of tools available now to study and manipulate
these parasites.
Indeed, now that the genome sequence has been determined,
many obviously conserved processes have been dissected, and the
core molecular cartography of mRNA and protein expression has
provided a framework for more hypothesis-driven analyses, the
next 25 years promise exciting new discoveries focussed on the dis-
tinct biology of the parasite and the abundance of genes for which
no function can be predicted a priori. The future will be unexpected,
but some key areas need to be explored further. For example,rypanosome research: From description to molecular dissection
rg/10.1016/j.molbiopara.2015.01.006
trypanosome biologists, with notable exceptions, have tended to
ignore the interactions of the parasite with the host immune sys-
tem, except at the most rudimentary level. It is likely that the
sophistication of these parasites, able to sustain chronic infections
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n multiple hosts, will reveal new immunomodulatory phenomena
f importance to the infection dynamics of the parasite. This is
lso true in the tsetse ﬂy vector, where immune interactions with
rthropod defences will have strong impact on the transmission
apability of trypanosomes between hosts. Also the interactions
f different parasites populations in the ﬁeld remain poorly char-
cterised. The Plasmodium ﬁeld has been particularly effective at
nalysing and studying ﬁeld strains to understand the biology of
hat parasite, but in trypanosomes population analyses in a ﬁeld
etting have been relatively limited [191–193], with a strong focus
n only a single laboratory adapted strain whose biology and even
rug sensitivity may  show important differences. The interaction
f T. brucei with other trypanosomes (and potentially other para-
ites) is also an emerging theme – with social interactions between
rypanosomes both in the tsetse ﬂy (social motility) [194,195] and
n the bloodstream (quorum sensing) [196] providing an impor-
ant component to their life history with fascinating evolutionary
nd cell biological implications, relevant across a broad range of
icrobes.
As well as these whole organism questions, reductionist details
re still very incomplete in many areas of trypanosome molec-
lar biology. Despite the characterisation of many molecular
omponents, we still do not understand how gene regulation
s co-ordinated, or how signalling pathways connect to gener-
te a coherent cellular response to the environment. Even the
achinery underlying VSG expression control and switching is
nly characterised in outline, as are the molecular controls under-
ying the parasite’s cell cycle and the co-ordination between the
uclear and organelle replication and division cycles. The num-
er of manuscripts published on Trypanosoma brucei has increased
very year and shows no sign of diminishing. It is incumbent on the
eld to continue to ask interesting questions and discover striking
ovelty, rather than just increasing detail on established processes,
n order to retain the interest of the wider scientiﬁc community and
rovide important new insight into basic biological processes. This
s the challenge for the next 25 years.
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